A research of efficacy and safety of oxytocin administration to detect others altruism in children and adolescents with reactive attachment disorder.

A research of efficacy and safety of oxytocin administration to detect others altruism in children and adolescents with reactive attachment disorder. - Oxytocin administration to detect others altruism for RAD.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016389

Enrollment

Registered

2015-01-31

Start date

2015-01-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reactive attachment disorder Autism-spectrum disorder

Interventions

Intranasal single administration of oxytocin Intranasal single administration of placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with reactive attachment disorder or autism spectrum disorder based on the classifications in the diagnostic and statistical manual of mental disorders (DSM-5). Healthy children and adolescents with higher level of IQ 80. 2) Subjects within the age range of 10-17 years old. 3) Must demonstrate an acceptable degree of compliance with medication and procedures in the opinion of the investigator.

Exclusion criteria

Exclusion criteria: 1. History of allergy for oxytocin. 2. Subject who haven't been informed his/her diagnosis at getting a consent. 3. Subjects who have any other current DSM-5 diagnosis of the following; "Schizophrenia and Other Psychotic Disorders","Delirium, Dementia, and Amnestic and Other Cognitive Disorders", "Substance-Related Disorders", "eating disorders","personality disorders". 4.Subjects who have a physical disorder with a need of strict diet, or a diagnosis of a severe physical disorder. 5. Subject who is administrated any antipsychotic drugs except for atypical antipsychotic. 6. Women who are breastfeeding, pregnant, possibility of pregnancy, or have a wish of early pregnancy. 7. Subjects who are planned for an immediate therapeutic plan change due to unstable physical or psychological symptoms. 8. Subjects who, in the Investigator's opinion, might not be suitable for the study.

Design outcomes

Primary

Measure	Time frame
Comparison of score of cognitive tasks change after oxytocin or placebo administration.	—

Secondary

Measure	Time frame
salivary oxytocin concentration oxytocin receptor gene polymorphism neuropsychological test	—

Countries

Japan

Contacts

Public ContactAkemi Tomoda

University of Fukui, Research Center for Child Mental Development Division of Psychosocial Support for Nurturing

atomoda@u-fukui.ac.jp0776-61-8677

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026